Willliam Wigington, DO
Gastroenterology · Rogers, ARNPI 1114028701
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 377 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by AbbVie at 50.8% of the total.
Across 377 payments — averaging $14.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Takeda Pharmaceuticals U.S.A., Inc.$478
- Pfizer$457
- Johnson & Johnson$336
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$333
- Sanofi$135
- plus $1K from 26 others
What the payments were for
- Food & beverage$5,57299%
- Education$371%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 208 | $2,847 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $478 |
| Pfizer | 34 | $457 |
| Johnson & Johnson | 21 | $336 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 21 | $333 |
| Sanofi | 8 | $135 |
| QOL Medical, LLC | 8 | $118 |
| Ipsen Biopharmaceuticals, Inc | 6 | $118 |
| Regeneron Healthcare Solutions, Inc. | 6 | $111 |
| Gilead | 5 | $87 |
| Lilly USA, LLC | 3 | $74 |
| Cook Medical LLC | 2 | $50 |
| Laborie Medical Technologies Corp. | 1 | $46 |
| Aimmune Therapeutics, Inc. | 2 | $39 |
| Alfasigma USA, Inc. | 2 | $39 |
| Intercept Pharmaceuticals, Inc. | 2 | $39 |
| Medtronic | 1 | $29 |
| AMAG Pharmaceuticals, Inc. | 2 | $27 |
| Ironwood Pharmaceuticals, Inc | 2 | $25 |
| Amgen | 1 | $25 |
| Merck | 1 | $24 |
| Ardelyx, Inc. | 1 | $22 |
| Boston Scientific | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Micro-tech Endoscopy USA, Inc. | 1 | $16 |
| Bristol Myers Squibb | 1 | $15 |
| Madrigal Pharmaceuticals | 1 | $15 |
| Celltrion USA Inc. | 1 | $15 |
| Braintree Laboratories, Inc. | 1 | $13 |
| Boehringer Ingelheim | 1 | $13 |
| Olympus America Inc. | 1 | $12 |
| Echosens North America, Inc. | 1 | $10 |
How this compares
$5,609 in reported general payments places this provider in the 60th percentile of 108 gastroenterology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 13 | $349,459 |
| CreonLipase/Protease/Amylase | 32 | $134,056 |
| XifaxanRifaximin | 22 | $105,676 |
| Humira(Cf) PenAdalimumab | 12 | $81,739 |
| LinzessLinaclotide | 23 | $18,206 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 32 | $5,218 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 316 | $4,423 |
| Dexlansoprazole DrDexlansoprazole | 18 | $4,029 |
| Budesonide DrBudesonide | 33 | $3,602 |
| Ondansetron OdtOndansetron | 20 | $3,082 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 179 | $2,361 |
| Mercaptopurine | 26 | $1,677 |
| Sucralfate | 18 | $1,656 |
| Pantoprazole Sodium | 104 | $1,046 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 33 | $812 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $336 | $349,45913 claims |
| AbbVieCreon, Linzess | $2,847 | $152,26155 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $333 | $105,67622 claims |
| Braintree Laboratories, Inc.Sutab | $13 | $5,21832 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 108 gastroenterology providers in Arkansas.
Other gastroenterology in Rogers
- Vijay Bhaskar GayamRogers$12K
- Christopher MillerRogers$7K
- Robert WellsRogers$6K
- Glenn DavisLittle Rock$2.7M
- Ranga BalasekaranSpringdale$235K
- Ali KhanLittle Rock$49K
- Jaymie PenningtonLittle Rock$17K
- Michael JohnsonLittle Rock$17K
- David BackstedtLittle Rock$16K
- Hrair SimonianFort Smith$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.